Suppr超能文献

口服提取物通过增强软骨终板的血管生成促进腰椎椎间融合。

Oral extract promotes lumbar interbody fusion by enhancing vascularization of cartilage endplate.

作者信息

Zhen Ruixin, Li Jiaqi, Li Shaorong, Wu Han, Zhang Wei

机构信息

Department of Spine Surgery, First Hospital of Hebei Medical University, Shijiazhuang, China.

Department of Spine Surgery, Affiliated Hospital of Chengde Medical University, Chengde, China.

出版信息

Front Surg. 2025 Aug 29;12:1652156. doi: 10.3389/fsurg.2025.1652156. eCollection 2025.

Abstract

OBJECTIVE

This study aims to investigate the effect of oral (ES) extract on intervertebral fusion in a rabbit model.

METHODS

A rabbit lumbar lateral interbody fusion model was established. Different treatments were administered to each group, including the control group (CON), oral ES extract group (ES), interbody fusion group (IBF) and interbody fusion combined with oral ES group (IBF/ES). Ten weeks after surgery, micro-CT was used to assess intervertebral bone fusion. Bone trabecula parameters, including bone volume fraction (BV/TV), trabecular number (Tb.N) and trabecular thickness (Tb.Th), were measured. Histological analyses, including Masson and HE staining, were used to evaluate angiogenesis and bone growth in the endplate.

RESULTS

The micro-CT at the 10th postoperative week showed significant bone tissue regeneration and stable fusion in the IBF/ES groups. Fusion scores, BV/TV, Tb.N and Tb.Th were significantly higher in the IBF/ES groups compared to the other groups. In addition, Masson and HE staining indicated evident vascular ingrowth and new bone formation after oral ES extract treatment. Among the four groups, the IBF/ES groups showed the most significant bone formation and the best fusion effect.

CONCLUSION

This study suggested that oral ES extract after spine surgery can significantly enhance the effectiveness and success rate of lumbar lateral fusion surgery by promoting endplate vascularization and bone formation.

摘要

目的

本研究旨在探讨口服(ES)提取物对兔椎间融合模型的影响。

方法

建立兔腰椎外侧椎间融合模型。对每组进行不同治疗,包括对照组(CON)、口服ES提取物组(ES)、椎间融合组(IBF)和椎间融合联合口服ES组(IBF/ES)。术后10周,采用显微CT评估椎间骨融合情况。测量骨小梁参数,包括骨体积分数(BV/TV)、骨小梁数量(Tb.N)和骨小梁厚度(Tb.Th)。采用包括Masson染色和HE染色在内的组织学分析来评估终板中的血管生成和骨生长情况。

结果

术后第10周的显微CT显示,IBF/ES组有明显的骨组织再生和稳定融合。与其他组相比,IBF/ES组的融合评分、BV/TV、Tb.N和Tb.Th显著更高。此外,Masson染色和HE染色表明口服ES提取物治疗后有明显的血管长入和新骨形成。在四组中,IBF/ES组的骨形成最显著,融合效果最佳。

结论

本研究表明,脊柱手术后口服ES提取物可通过促进终板血管化和骨形成,显著提高腰椎外侧融合手术的有效性和成功率。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf75/12425786/93e41b32d60d/fsurg-12-1652156-i001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验